Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Great volume continues
View:
Post by Yajne on Dec 03, 2021 11:49pm

Great volume continues

...almost 3.4 million on all Cdn exchanges today plus over 1 million on TLTFF (US). Seems to me the word is starting to get out despite TLT's under the radar approach. If volume/interest can be maintained, the momentum provides an excellent springboard for the next round of NR's when mainstream media will hopefully pick up and amplify this wonderful story. Then these sub$1 days should finally be over.
Comment by floatinketucky on Dec 04, 2021 7:22am
I agree and folks are starting to see the murky water of the intial ph2 treatments get flushed out by the clear and very favorable data continuing to stream in. This coupled with the FDA wanting to know. The verification of data in this PH2 PIVITOL STUDY is what is making the value in the stcok so apparant. And awareness of the completly amazing results of the ph1 trial is also starting to get ...more  
Comment by StevenBirch on Dec 04, 2021 10:46am
Yes and I'm not a technical analyst, not a big fan, but this heavy volume should mean we are building a good support level here although I'm more inclined to think we keep climbing higher, with some breathers, until either the next report or anticipation of a surprise news release.  When I look at my account there is a nice profit now, finally, and some people would think I was crazy ...more  
Comment by prophetoffacts on Dec 04, 2021 10:54am
This post has been removed in accordance with Community Policy
Comment by menoalittle on Dec 04, 2021 12:00pm
>> The clinical trial data was released in a low key way... ah.... yeah.  No doubt about it. Fact is, it wasn't just the clinical trial data.  It started with the Nov. 15th news release, if you really think about it.  What was and wasn't said... how it was said...  If/when you start pondering the why's and wherefore's and connecting dots of the ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250